Oxford/AstraZeneca vaccine: rare blood clot syndrome has high mortality rate | Coronavirus | The Guardian

by health and nutrition advice journalist

Although extremely rare, a blood clot syndrome after the first dose of the Oxford/AstraZeneca vaccine carries a high risk of death and can occur in otherwise young and healthy people, UK researchers have found.

In those aged under 50, this blood clot syndrome occur in around one in 50,000 people who have received the vaccine, and that number falls to one in 100,000 in the over 50s, data suggests. But the risk of blood clots is much higher with Covid itself — research shows that more than a fifth of hospitalised patients with Covid have evidence of blood clots.

Researchers examined the symptoms, signs and outcomes in 220 confirmed and probable cases who presented in UK hospitals between 22 March and 6 June.

“It’s important to stress that this kind of reaction to the Oxford/AstraZeneca vaccine is very rare,” said Dr Sue Pavord, consultant haematologist at Oxford University Hospitals NHS Foundation Trust and lead author of the analysis published in the New England Journal of Medicine.

But for those who do develop blood clots, the results “can be devastating,” she added. “It often affects young, otherwise healthy vaccine recipients and has high mortality. It is particularly dangerous when the patient has a low platelet count and bleeding in the brain.”

“It can affect anybody,” added Beverley Hunt, medical director of Thrombosis UK and professor of thrombosis and haemostasis at King’s College London.

50% of the cases in the analysis had no previous medical illness, and there appeared to be no particular individual risk factors for the syndrome, Hunt said.

Researchers found that the syndrome – named vaccine-induced immune thrombocytopenia and thrombosis (VITT) – killed 23% of the cases analysed. This risk of death increases significantly to 73% in patients with a very low platelet count and brain bleeds after blood clots in the brain, they said.

VITT is similar to the condition sometimes reported in patients treated with the blood thinner heparin, but it seems to be “more aggressive than what we were familiar with,” said Pavord.

The researchers defined VITT based on five criteria, including onset of symptoms 5 to 30 days after vaccination, a low platelet count, and documented presence of a blood clot.

Although there a few reports of a rare blood clotting side-effects after Pfizer/BioNTech vaccine, in the way that VITT has been defined – these cases appear to be only associated with the Oxford/AstraZeneca jab, the researchers also said.

“We’ve kept an open mind,” said Dr Catherine Bagot, consultant haematologist at Glasgow Royal Infirmary, and senior clinical lecturer at the University of Glasgow. “The Pfizer vaccine has not – for the cases that we are aware of – been able to meet the definition either of a confirmed case or a probable case.”

In early May, the Joint Committee on Vaccination and Immunisation (JCVI) recommended people under the age of 40 be offered an alternative to the Oxford/AstraZeneca vaccine where possible while infection rates remain low, after reports of very rare blood clots after first shots of the vaccine.

In the 220 confirmed and probable VITT cases in the analysis, ages ranged from 18 to 79 years, with a median of 48 years. About 85% were under the age of 60, despite most of the elderly population having been vaccinated.

But this does not mean the Oxford/AstraZeneca vaccine should not be given to the under-60s, Pavord said.

“If there’s high prevalence of Covid, more people are likely to end up infected and in critical care, and if they’re over-60, more likely to die. In that case, it makes sense to give Oxford/AstraZeneca to everybody. But when there’s a lower prevalence of Covid, an age limit would be appropriate, she said.

“What is absolutely crucial to consider is the bigger picture – and that is the risk of Covid is much greater for the older age groups.”

This content was originally published here.

Share this article

Leave a comment

Your email address will not be published. Required fields are marked *